Inhibition of interleukin-6 decreases atrogene expression and ameliorates tail suspension-induced skeletal muscle atrophy

Mitsutaka Yakabe¹, Sumito Ogawa¹*, Hidetaka Ota¹, Katsuya Iijima¹, Masato Eto¹, Yasuyoshi Ouchi¹,², Masahiro Akishita¹

¹ Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ² Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Minato-ku, Tokyo, Japan

* suogawa-ty@umin.ac.jp

Abstract

Background
Interleukin-6 (IL-6) is an inflammatory cytokine. Whether systemic IL-6 affects atrogene expression and disuse-induced skeletal muscle atrophy is unclear.

Methods
Tail-suspended mice were used as a disuse-induced muscle atrophy model. We administered anti-mouse IL-6 receptor antibody, beta-hydroxy-beta-methylbutyrate (HMB) and vitamin D to the mice and examined the effects on atrogene expression and muscle atrophy.

Results
Serum IL-6 levels were elevated in the mice. Inhibition of IL-6 receptor suppressed muscle RING finger 1 (MuRF1) expression and prevented muscle atrophy. HMB and vitamin D inhibited the serum IL-6 surge, downregulated the expression of MuRF1 and atrogin-1 in the soleus muscle, and ameliorated atrophy in the mice.

Conclusion
Systemic IL-6 affects MuRF1 expression and disuse-induced muscle atrophy.

Introduction
Skeletal muscle atrophy occurs in many chronic diseases and under conditions of disuse, such as denervation and immobilization [1]. Particularly among the elderly, atrophy can cause sarcopenia and lead to adverse outcomes such as physical disability, poor quality of life and high mortality [2].
Several mechanisms are thought to be involved in disuse-induced muscle atrophy. One mechanism is increased proteolysis. In atrophying muscle, protein degradation is increased through the activation of the ubiquitin-proteasome pathway. The two atrogenes muscle RING finger 1 (MuRF1) and atrogin-1 are well-studied ubiquitin ligases that are thought to promote atrophy. These genes have been identified as molecular mediators of muscle atrophy [3, 4] and are upregulated during atrophy due to conditions such as denervation and immobilization, and mice deficient in either MuRF1 or atrogin-1 have been found to be resistant to atrophy [3]. Forkhead box O (FOXO) transcription factors are known to be recruited to the promoters of MuRF1 and atrogin-1 to activate the transcription of these genes [5, 6]. Unloading-associated muscle atrophy has been supposed to be driven by signals in the immobilized region, rather than systemic factors [7].

Beta-hydroxy-beta-methylbutyrate (HMB) is a metabolite of leucine, one of the ketogenic amino acids. Several studies have focused on the effects of HMB on atrogen expression. HMB prevented dexamethasone-induced muscle wasting by inhibiting the MuRF1 and atrogin-1 expression in rat myotubes in vitro [8]. HMB also attenuated dexamethasone-induced muscle atrophy by regulating FOXO transcription factor and subsequent MuRF1 expression in rats [9]. In aged male rats, HMB reduced the expression of MuRF1 [10]. HMB has also been suggested to repress the expression of IL-6 [11, 12]. 1,25-dihydroxyvitamin D (1,25(OH)₂D₃) is the hormonal form of vitamin D [13], and most of their function is mediated by a nuclear receptor Vitamin D receptor (VDR). 1,25(OH)₂D₃ and other forms of vitamin D have been shown to repress IL-6 in vitro and in vivo [14, 15]. One study has reported that 1,25(OH)₂D₃ downregulated MuRF1 and atrogin-1 expression in human myotubes [16]. In this way, HMB and 1,25(OH)₂D₃ have been supposed to possess both anti-atrophic effects and IL-6-repressing effects, but the relationship between these effects is unclear.

IL-6 is a pleiotropic cytokine that acts as both a myokine and an inflammatory cytokine [17]. IL-6 is produced by various cells, including monocytes, fibroblasts, vascular endothelial cells and skeletal muscles [18, 19]. IL-6 is released into the systemic circulation from muscles during acute exercise-mediated skeletal muscle contraction [20]. It activates the proliferation of cells in skeletal muscles, including satellite cells [21, 22]. In cultured C2C12 myotubes, knockdown of IL-6 reduced the expression of myogenic factors such as myogenin and α-actin [23]. In genomic IL-6 knockout mice, overloading of muscles failed to induce the expression of the myogenic marker MyoD [24] or to promote satellite cell proliferation [25]. However, some studies have implicated IL-6 in muscle atrophy. Chronic IL-6 administration directly to skeletal muscles induced atrophy [26]. IL-6-transgenic mice exhibited muscle atrophy, which was inhibited by MR16-1, an anti-mouse IL-6 receptor (IL-6R) antibody [27]. In humans, a longitudinal study in the elderly showed that high serum IL-6 level were associated with muscle loss [28]. According to the concept of “inflamm-aging (inflammation + aging)”, inflammatory cytokines, including IL-6, may be involved in age-related diseases, such as atherosclerosis, dementia, type 2 diabetes and osteoporosis [29, 30], and inflamm-aging might also be involved in sarcopenia [31].

Studies using unloading-induced atrophy model have shown that the expression of IL-6 is elevated in the immobilized muscles or skins [32, 33]. However, to the best of our knowledge, no study has examined the effects of systemic IL-6 on disuse-induced muscle atrophy or atrogenes. Furthermore, few studies have examined whether vitamin D and HMB ameliorate disuse-induced muscle atrophy, or whether the effect is via IL-6-related pathways. Therefore, we hypothesized that the inhibition of systemic IL-6 in a disuse-induced muscle atrophy model might be a strategy to repress atrogene expression and to counteract the atrophy. We also hypothesized that anti-atrophic effects of vitamin D and HMB work via IL-6-related pathways. In the present study, we adopted a tail-suspended mouse model, which has been widely used.
to simulate disuse-induced muscle atrophy [3, 34], and focused on MuRF1 and atrogin-1. After tail suspension was initiated, the maximal reduction in muscle mass was observed by day 14 [35]. Compared with that in control mice, the expression of MuRF1 and atrogin-1 was significantly upregulated by day 3 in the mice subjected to tail suspension; then, the expression of these factors peaked and became similar to control levels by day 14 [36, 37]. We also examined the effects of MR16-1, HMB and vitamin D on atrogene expression and muscle atrophy in the mice. Our data suggested a role of systemic IL-6 in ameliorating muscle atrophy.

Methods
Materials
HMB (calcium salt) was purchased from Alfa Aesar (MA, USA). 1,25(OH)2D3 was purchased from Sigma-Aldrich Japan (Tokyo, Japan). MR16-1, a monoclonal mouse IL-6R-blocking antibody, was donated by Chugai Pharmaceutical Company (Tokyo, Japan).

Mice
Male C57BL/6J mice were purchased from Nippon CLEA (Tokyo, Japan). The animals were individually housed in similarly designed cages and maintained in a controlled environment (temperature of 24±1˚C, humidity of 55 ± 5%) with a 12:12 h light:dark cycle. The mice received standard chow and water ad libitum. After the mice were acclimatized for two weeks, the experiments commenced.

The experimental protocol was approved by the Ethics Committee for Animal Research at the University of Tokyo (permit number: 13-P-66). Animal health was monitored in accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals (the Japanese Society for Laboratory Animal Resources). A humane endpoint was determined according to the criteria of the Japanese Society for Laboratory Animal Resources. At the end of the planned experiments, the mice were immediately euthanized with carbon dioxide. All efforts were made to minimize suffering. No animals died before meeting the criteria for euthanasia.

Comparison of aged and young mice

The mice were maintained for approximately two years and monitored at least three times a week. One mouse was excluded because it had a tumor and became severely cachexic with age. Finally, five mice reached 104 weeks of age and were then sacrificed. The soleus muscles were weighed, and serum samples were evaluated using IL-6-specific ELISA as described below. As a controls, 15-week-old mice were sacrificed (n = 4).

Tail suspension

Mice were subjected to tail suspension, which induced muscle atrophy in their hindlimbs. The tail-suspension protocol was as follows. The entire tail of the mouse was covered and protected with medical adhesive tape. A harness made of the tape was attached to the proximal half of the tail, and the mouse was suspended so that the feet of the hindlimbs could not contact the cage floor. The tail was kept horizontal to the floor. The distal end of the harness was attached to a paperclip, which was then attached to a swivel on a cross-bar. The cross-bar was positioned approximately 15 cm above the cage floor. The tail-suspended mice were able to move freely on their forelimbs in the cage and had free access to food and water ad libitum.

Twelve-week-old mice were subjected to two weeks of tail suspension. The mice were sacrificed, and the serum samples and soleus muscles were then collected. The serum IL-6 level was
determined using ELISA as described below. In another experiment, twelve-week old mice were subjected to seven days of tail suspension. The mice were sacrificed, and RNA was extracted from the following tissues: whole bone marrow from femurs, soleus muscles, livers, spleens, and small intestines. These mice were compared with control mice of the same age. During the experiment, the mice were monitored each day, and none of the mice were found to exhibit health or behavioral problems.

Administration of 1,25(OH)$_2$D$_3$ or HMB

Eleven-week-old mice were divided into four groups (each n = 4): control, tail suspension, tail suspension+1,25(OH)$_2$D$_3$, and tail suspension+HMB. Both 1,25(OH)$_2$D$_3$ and HMB were administered daily by gavage. The former was dissolved in normal corn oil and administered at 0.1μg/kg/day, and the latter was dissolved in distilled water and administered at 340 mg/kg/day similar to previous studies [38, 39]. The control mice received both corn oil and water. Administration was commenced one week before the mice were subjected to tail suspension and was continued during the tail suspension period. To measure muscle weight and cross-sectional area (CSA), the mice were subjected to tail suspension for two weeks and then sacrificed. The muscles were collected and embedded in paraffin blocks. Subsequently, 5-μm sections were cut from the blocks using a Leica microtome (Leica Instruments GmbH, Hubloch, Germany) and transferred to adhesive-coated slides. Hematoxylin-eosin (HE) staining was performed, and the average CSA of the muscles was calculated using ImageJ version 1.44 (National Institutes of Health, USA).

For soleus muscle RNA analysis, other groups of mice were treated with the agents, subjected to tail suspension for three days and then sacrificed.

RNA analysis

The collected samples (soleus muscles and whole bone marrow) were immersed in RNAlater (Qiagen, CA, USA) to stabilize the RNA in tissues. RNA extraction and DNase I treatment were performed using an RNeasy Fibrous Tissue Mini Kit (Qiagen). cDNA was synthesized from the RNA samples using the Omniscript RT Kit (Qiagen) and oligo (dT) primers (Invitrogen, CA, USA). The cDNA was mixed with SYBR Green Master Mix (Applied Biosystems, CA, USA) and specific primers for each gene (total amount: 20 μl) and then subjected to quantitative real-time PCR using a 7300 Real-Time PCR System (Applied Biosystems). The amount of amplified cDNA was determined based on the fluorescence of SYBR Green. A dissociation curve was generated to examine the specificity of the PCR reaction. The cycle threshold (Ct) for each gene was normalized to that for GAPDH, which was used as the internal control. All real-time PCR experiments were conducted in triplicate. The primer sequences are shown below.

GAPDH: 5’-AGGTCCGTTGTAACGATTTG-3’ (forward) and 5’-TGTAGACCAGTAAGTGGGCT-3’ (reverse);
IL-6: 5’-TAGCTCTTCTACCTACATG-3’ (forward) and 5’-TTGCTCTTTAGC-3’ (reverse);
MuRF1: 5’-TGACTGGGATGTGTTAACCAGC-3’ (forward) and 5’-AAACGACCTCCAAGCATG-3’ (reverse); and
atrogen-1: 5’-AGGTCTTGTGAGGATAGT-3’ (forward) and 5’-CACCACATGTG-3’ (reverse).

MR16-1 administration protocol

Eleven-week-old C57BL/6J mice were administered MR16-1 via intraperitoneal injection and subjected to tail suspension. The administration protocol, which was recommended by Chugai
Pharmaceutical Company, is shown in Fig 1. To examine the expression MuRF1 and atrogin-1 in the soleus muscles, the mice were subjected to two days of tail suspension (Fig 1A). To measure soleus muscle weight and CSA, another group of mice were subjected to two weeks of tail suspension (Fig 1B).

Mouse IL-6 ELISA
Mice were divided into five groups: control, tail suspension, tail suspension+1,25(OH)2D3, tail suspension+HMB, and tail suspension+1,25(OH)2D3+HMB (each n = 4). After one week of pretreatment, the mice were subjected to two weeks of tail suspension. The serum IL-6 level was determined using a mouse IL-6 ELISA Kit (Ray Biotech, GA, USA) according to the manufacturer’s protocol.

Statistical analysis
Data are expressed as the mean ±SEM. Comparisons between two groups were performed using Student’s t-test. Comparisons among multiple groups were performed using ANOVA. A value of P<0.05 was considered significant.

Results
Characteristics of tail-suspended mice and aged mice
Mice that were subjected to tail suspension for two weeks exhibited significantly increased serum IL-6 levels (Fig 2A). Tail suspension also induced soleus muscle atrophy, resulting in a decrease in the soleus muscle weight/body weight ratio. To determine the tissue of origin of increased IL-6 in the serum, we subjected another group of mice to seven days of tail suspension and extracted RNA from the following candidate tissues: whole bone marrow from femurs, soleus muscles, livers, spleens, and small intestines. IL-6 expression levels in the bone marrow of these mice were higher than those of the control mice (Fig 2B). In the soleus muscles, no increase in the IL-6 expression was observed. No significant differences were observed in the other tissues.

We also examined the serum IL-6 levels and soleus muscle weight in young and aged mice. The serum IL-6 level was higher in the 104-week-old mice than that in the 15-week-old mice.
Fig 2. Characteristics of tail-suspended mice and aged mice. (A) Twelve-week-old C57BL/6J male mice were subjected to two weeks of tail suspension. Mice were sacrificed, and then serum samples and soleus muscles were collected. Serum IL-6 level was determined using ELISA. Soleus muscle weight and body weight were measured. (B) Relative expression of IL-6 in bone marrow, soleus muscle, liver, spleen, and small intestine. (C) Serum IL-6 level, soleus muscle weight, and body weight were measured at 15 weeks and 104 weeks.
The aged mice were heavier than their younger counterparts, and the soleus muscle weight/body weight ratio was lower in the aged mice than that in the young mice.

Effects of IL-6 inhibition on atrogene expression and muscle atrophy

To examine the effect of IL-6 inhibition on tail suspension-induced muscle atrophy, we administered mice with MR16-1, a monoclonal mouse IL-6R-blocking antibody, according to the protocol shown in Fig 1. The expression of MuRF1 and atrogin-1 in the soleus muscles was significantly increased after two days of tail suspension (Fig 3A). MR16-1 significantly inhibited MuRF1 expression and did not repress atrogin-1 expression.

Another group of mice were subjected to two weeks of tail suspension. MR16-1 significantly ameliorated the reduction in the soleus muscle weight/body weight ratio (Fig 3B). No significant difference in body weight was observed between the tail suspension group and the tail suspension+MR16-1 group. Although the difference was not significant (p = 0.09), MR16-1 also restored the CSA of the soleus muscles (Fig 3C).

HMB and vitamin D ameliorated muscle atrophy induced by tail suspension

We determined whether 1,25(OH)_{2}D_{3} and HMB could affect atrogene expression and ameliorate muscle atrophy. Both 1,25(OH)_{2}D_{3} or HMB inhibited the increase in MuRF1 and atrogin-1 expression (Fig 4A). Two weeks of tail suspension induced muscle atrophy, and both 1,25(OH)_{2}D_{3} and HMB ameliorated this atrophy (Fig 4B). The CSA of the soleus muscle was reduced by tail suspension, and both 1,25(OH)_{2}D_{3} and HMB partially restored the CSA values (Fig 4C).

Effects of 1,25(OH)_{2}D_{3} and HMB on serum IL-6 levels

To examine the effects of 1,25(OH)_{2}D_{3} and HMB on the tail suspension-induced serum IL-6 surge, we used another group of mice. This time, the mice were divided into five groups: control, tail suspension, tail suspension+1,25(OH)_{2}D_{3}, tail suspension+HMB, and tail suspension+1,25(OH)_{2}D_{3}+HMB (each n = 4). After one week of pretreatment, the mice were subjected to two weeks of tail suspension. Although the difference was not significant, both 1,25(OH)_{2}D_{3} and HMB inhibited the IL-6 surge (p = 0.15 and 0.17, respectively). When 1,25(OH)_{2}D_{3} and HMB were administered in combination, the IL-6 surge was significantly inhibited (Fig 5).

Discussion

In the present study, we demonstrated that the serum IL-6 level was elevated in mice subjected to tail suspension and that the inhibition of IL-6R ameliorated the resulting muscle atrophy. The expression of MuRF1 was repressed by the inhibition of IL-6R, but the expression of atrogin-1 was not affected. The novelty of the present study is that systemic IL-6 might be involved in unloading-induced atrophy, and that the inhibition of IL-6 repressed the atrophy. We also showed that both 1,25(OH)_{2}D_{3} and HMB inhibited atrogene expression and muscle atrophy in mice.
Amelioration of tail suspension-induced skeletal muscle atrophy mediated by IL-6 inhibition

A

MuRF1

atrogin-1

B

Soleus muscle weight

Body weight

C

CSA (soleus muscles)

control

suspended

MR16.1+suspended
Several disuse-induced atrophy models have been developed and examined in addition to the tail suspension model. One is the cast immobilization model, in which the unilateral hindlimb is wrapped in casting tape so that the hip, knee, and ankle are flexed. When rats were subjected to this intervention for four weeks, the expression of TNFα and IL-6 was elevated in the hindlimb skin [33]. In the present study, the serum IL-6 level and IL-6 expression in the whole bone marrow were elevated in the tail-suspended mice (Fig 2A and 2B). This finding is consistent with the results of a previous study that reported the induction of IL-6 secretion from bone marrow stromal cells by tail suspension [40]. Some studies have suggested the relation between endotoxin and tail suspension. Gut motility is slower during exposure to microgravity [41]. Vascular changes including increased blood flow to the gastrointestinal tract have been reported after tail suspension [42]. Compared to those in non-suspended mice, the level of LPS in the portal vein and neutrophil count and steatosis in the liver are increased in tail-suspended mice [43]. The portal vein endotoxin levels are approximately 100 pg/mL [43]. It is possible that the intestinal mucosal barrier is damaged in tail-suspended mice, which results in the translocation of bacteria and endotoxins from the gut lumen into the circulation. In the present study, the expression of IL-6 in the liver was not significantly elevated on day 7 after tail suspension (Fig 2B). Thus, although elevated serum LPS levels might have induced IL-6 expression in the bone marrow cells, this may not have been sufficient to increase the IL-6 expression in the liver.

We did not observe elevated IL-6 expression in the soleus muscles or other tissues (Fig 2B). Therefore, it is unlikely that the serum IL-6 was derived from soleus muscles or other atrophyizing muscles. It is possible that tail suspension increases the load on the forelimbs of the mice and that forelimb skeletal muscles produced IL-6 similar to that observed during exercise. However, the forelimbs are loaded similarly to the control mice during tail suspension [44], and the weight of forelimb muscles is not increased in rats after fourteen days of tail suspension [45]. Taken together, the elevated serum IL-6 is unlikely to have originated from skeletal muscles.

In the present study, inhibition of IL-6 partially ameliorated the muscle atrophy (Fig 3B and 3C). IL-6 transgenic mice exhibit decreased skeletal muscle mass, and an anti-mouse IL-6R antibody completely abrogates atrophy [27]. A previous study showed that IL-6 alters the phosphorylation of ribosomal S6 kinase and STATs (Signal Transducers and Activator of Transcriptions), indicating a shift in the balance of growth factor-related signaling toward a more catabolic profile [26]. Another study suggested that IL-6 and serum amyloid A produced in the liver synergistically increase MuRF1 and atrogin-1 expression by inducing SOCS-3 expression and impairing its downstream insulin/IGF-1 signaling in skeletal muscles [46]. Likewise, the serum IL-6 might alter the phosphorylation of ribosomal S6 kinase and STATs and might even work with amyloid A to affect atrogene expression in tail-suspended mice. MuRF1 and atrogin-1 share several regulatory factors such as FoxO, MAPK and NF-κB [5, 6, 47]. In our study, MuRF1 expression was inhibited by MR16-1, while atrogin-1 expression was not (Fig 3A), indicating that these genes are differentially regulated by IL-6. The effects of MR16-1 on muscle atrophy was partial (Fig 3B and 3C), suggesting that IL-6 is not the only
Amelioration of tail suspension-induced skeletal muscle atrophy mediated by IL-6 inhibition

A

**MuRF1**

| Treatment | Relative expression |
|-----------|---------------------|
| suspension | **-** 2.5 **+** 1.5 **+** 1 **+** 2 |
| 1.25(OH)D&sub;3 | - - + - |
| HMB | - - - + |

**atrogen-1**

| Treatment | Relative expression |
|-----------|---------------------|
| suspension | **-** 2 **+** 1 **+** 3 |
| 1.25(OH)D&sub;3 | - - + - |
| HMB | - - - + |

B

**Soleus muscle weight/body weight**

| Treatment | (mg/g body weight) |
|-----------|---------------------|
| suspension | **-** 0.4 **+** 0.3 **+** 0.4 |
| 1.25(OH)D&sub;3 | - - + - |
| HMB | - - - + |

**Body weight**

| Treatment | (g) |
|-----------|-----|
| suspension | **-** 25 **+** 20 **+** 25 |
| 1.25(OH)D&sub;3 | - - + - |
| HMB | - - - + |

C

**CSA (soleus muscles)**

| Treatment | (μm²) |
|-----------|-------|
| suspension | **-** 1400 **+** 1200 **+** 1400 |
| 1.25(OH)D&sub;3 | - - + - |
| HMB | - - - + |

1,25(OH)D&sub;3+suspended

HMB+suspended

PLOS ONE | https://doi.org/10.1371/journal.pone.0191318  January 19, 2018 10 / 15
factor involved in the development of disuse-induced muscle atrophy. Further studies are needed to elucidate the molecular mechanism by which IL-6 regulates atrogene expression in skeletal muscles.

We also showed that HMB and 1,25(OH)\textsubscript{2}D\textsubscript{3} significantly repressed the expression of atrogene and ameliorated atrophy (Fig 4A–4C). These compounds inhibited the tail suspension-induced serum IL-6 surge on day 14 (Fig 5). When 1,25(OH)\textsubscript{2}D\textsubscript{3} and HMB were administered in combination, their effect on the serum IL-6 surge was significant. As described in the Introduction section, 1,25(OH)\textsubscript{2}D\textsubscript{3} and HMB act via distinct mechanisms and thus have additive effects. One possibility is that these compounds repressed the atrogene expression via IL-6R by the inhibition of IL-6 expression. However, when only one of the compounds was administered, the serum IL-6 surge was not significantly inhibited. Thus, it is also possible that atrogene expression and serum IL-6 levels are regulated via independent pathways in response to HMB or 1,25(OH)\textsubscript{2}D\textsubscript{3}.

Few studies have previously shown that vitamin D represses atrogene expression [16]. However, we have demonstrated for the first time that vitamin D represses the expression of MuRF1 and atrogin-1 in a mouse model of disuse-induced atrophy. In one study, HMB administered to tail-suspended rats inhibited myonuclear apoptosis during the recovery from tail suspension-induced muscle atrophy in aged rats [48]. In the present study, pretreatment with HMB prevented muscle atrophy. Our data are consistent with those of previous studies,
showing that HMB represses the expression of MuRF1 and atrogin-1 [8–10]. In a previous study, HMB did not repress the expression of MuRF1 and atrogin-1 and did not protect rats from skeletal muscle atrophy induced by monolateral hindlimb immobilization [49]. In that study, immobilization was performed in one hindlimb by applying a cast with total plantar extension, and the knee was fully extended. The amount of HMB administered was 600 mg/kg/day, which is greater than the amount used in the present study. Differences in species and the method of immobilization may have affected the results.

In aged mice, the serum IL-6 level was higher and skeletal muscle mass was lower than those in their younger counterparts (Fig 2C). Disuse-induced muscle atrophy and aging-related atrophy are similar in some aspects but different in others. The plasma TNFα level is high in tail-suspended mice [43]. Some studies have suggested a relationship between inflammatory cytokines (such as IL-6 and TNFα) and sarcopenia in humans [28, 50]. Both MuRF1 and atrogin-1 are upregulated in denervated muscle, immobilized muscle [1], and the skeletal muscles of aged humans and rats [51, 52]. Disuse primarily causes slow fiber atrophy with a slow-to-fast fiber type shift [53], while age-related muscle atrophy is predominant in fast fibers [54]. The administration of MR16-1 in aged mice might provide us additional insights into the mechanisms by which IL-6 affects age-related muscle atrophy.

In summary, the inhibition of IL-6 can suppress atrogene expression and ameliorate tail suspension-induced muscle atrophy. Therefore, IL-6 inhibition may also be therapeutic for other types of muscle atrophy involving atrogens.

Author Contributions

Conceptualization: Sumito Ogawa.

Data curation: Mitsutaka Yakabe.

Investigation: Mitsutaka Yakabe.

Project administration: Mitsutaka Yakabe, Sumito Ogawa.

Supervision: Sumito Ogawa, Hidetaka Ota, Katsuya Iijima, Masato Eto, Yasuyoshi Ouchi, Masahiro Akishita.

Writing – original draft: Mitsutaka Yakabe.

Writing – review & editing: Mitsutaka Yakabe, Sumito Ogawa, Hidetaka Ota, Masahiro Akishita.

References

1. Foletta VC, White LJ, Larsen AE, Leger B, Russell AP. The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy. Pflugers Arch. 2011; 461:325–35. https://doi.org/10.1007/s00424-010-0919-9 PMID: 21221630

2. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39:412–23. https://doi.org/10.1093/ageing/afq034 PMID: 20392703

3. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294:1704–8. https://doi.org/10.1126/science.1065874 PMID: 11679633

4. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001; 98:14440–5. https://doi.org/10.1073/pnas.251541198 PMID: 11717410

5. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004; 117:399–412. PMID: 15109499
20. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev. 2016; 22:12184–94. https://doi.org/10.1074/jbcr.2016.010294 PMID: 27129272

19. Jonsdottir IH, Schjerling P, Ostrowski K, Asp S, Richter EA, Pedersen BK. Muscle contractions induce interleukin-6 mRNA production in rat skeletal muscles. J Physiol. 2000; 528 Pt 1:157–63. PMID: 10639646

18. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993; 54:1–78. PMID: 8379461

17. Baeza-Raja B, Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008; 9:321–49. https://doi.org/10.1016/j.cmet.2008.03.004 PMID: 18612045

16. Russ DW, Acksel C, Boyd IM, Maynard J, McCorrie KW, Edens NK, et al. Dietary HMB and beta-alanine co-supplementation does not improve in situ muscle function in sedentary, aged male rats. Appl Physiol Nutr Metab. 2015; 40:1294–301. https://doi.org/10.1139/apnm-2015-0391 PMID: 26579948

15. Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol (1985). 2005; 98:911–7. https://doi.org/10.1152/japplphysiol.01026.2004 PMID: 15542570
27. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest. 1996; 97:244–9. https://doi.org/10.1172/JCI118398 PMID: 8550842

28. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006; 119:526 e9-17. https://doi.org/10.1016/j.amjmed.2005.10.049 PMID: 16750969

29. Castelo-Branco C, Soveral I. The immune system and aging: a review. Gynecol Endocrinol. 2014; 30:16–22. https://doi.org/10.3109/09513590.2013.852531 PMID: 24219599

30. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000; 908:244–54. PMID: 10911963

31. Curtis E, Litwic A, Cooper C, Dennison E. Determinants of Muscle and Bone Aging. J Cell Physiol. 2015; 230:2618–25. https://doi.org/10.1002/jcp.25001 PMID: 25820482

32. Kang C, Ji LL. Muscle immobilization and remobilization downregulates PGC-1alpha signaling and the mitochondrial biogenesis pathway. J Appl Physiol (1985). 2013; 115:1618–25. https://doi.org/10.1152/japplphysiol.01354.2012 PMID: 23970536

33. Guo TZ, Wei T, Li WW, Li XQ, Clark JD, Kingery WS. Immobilization contributes to exaggerated neuropeptide signaling, inflammatory changes, and nociceptive sensitization after fracture in rats. J Pain. 2014; 15:1033–45. https://doi.org/10.1016/j.jpain.2014.07.004 PMID: 25063543

34. Wagatsuma A. Effect of hindlimb unweighting on expression of hypoxia-inducible factor-1alpha vascular endothelial growth factor, angiopoietin, and their receptors in mouse skeletal muscle. Physiol Res. 2008; 57:613–20. PMID: 17705680

35. Hanson AM, Harrison BC, Young MH, Stodieck LS, Ferguson VL. Longitudinal characterization of functional, morphologic, and biochemical adaptations in mouse skeletal muscle with hindlimb unweighting. Muscle Nerve. 2013; 48:393–402. https://doi.org/10.1002/mus.23753 PMID: 23893872

36. Okamoto T, Torii S, Machida S. Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles. J Physiol Sci. 2011; 61:537–46. https://doi.org/10.1007/s12576-011-0175-6 PMID: 21901639

37. Lloyd SA, Lang CH, Zhang Y, Paul EM, Laufenberg LJ, Lewis GS, et al. Interdependence of muscle atrophy and bone loss induced by mechanical unloading. J Bone Miner Res. 2014; 29:1118–30. https://doi.org/10.1002/jbmr.2113 PMID: 24127218

38. Alterman DE, Pereira SL, Edens NK, Hao Y, Bennett BT. beta-Hydroxy-beta-methylbutyrate (HMB) enhances the proliferation of satellite cells in fast muscles of aged rats during recovery from disuse atrophy. Exp Gerontol. 2013; 48:973–84. https://doi.org/10.1016/j.exger.2013.06.005 PMID: 23832076

39. Fu L, Tang T, Miao Y, Hao Y, Dai K. Effect of 1,25-dihydroxy vitamin D3 on fracture healing and bone remodeling in ovariectomized rat femora. Bone. 2009; 44:893–8. https://doi.org/10.1016/j.bone.2009.01.378 PMID: 19442605

40. Grano M, Mori G, Minielli V, Barou O, Colucci S, Giannelli G, et al. Rat hindlimb unloading by tail suspension reduces osteoblast differentiation, induces IL-6 secretion, and increases bone resorption in ex vivo cultures. Calcif Tissue Int. 2002; 70:176–85. https://doi.org/10.1007/s00223-001-2034-6 PMID: 11907715

41. Amidon GL, DeBrincat GA, Najib N. Effects of gravity on gastric emptying, intestinal transit, and drug absorption. J Clin Pharmacol. 1991; 31:968–73. PMID: 1761729

42. Deever DB, Young RS, Wang S, Bradshaw BA, Miles J, Pettis CR, et al. Changes in organ perfusion and weight ratios in post-simulated microgravity recovery. Acta Astronaut. 2002; 50:45–52. PMID: 11907715

43. Rivera CA, Tcharmtchi MH, Mendoza L, Smith CW. Endotoxemia and hepatic injury in a rodent model of hindlimb unloading. J Appl Physiol (1985). 2003; 95:1656–63. https://doi.org/10.1152/japplphysiol.00302.2003 PMID: 12749031

44. Morey-Holton ER, Globus RK. Hindlimb unloading of growing rats: a model for predicting skeletal changes during space flight. Bone. 1998; 22:838–843. PMID: 9600759

45. Somody L, Fagette S, Blanc S, Frutoso J, Gharib C, Gauquelin-Koch G. Regional blood flow in conscious rats after head-down suspension. Eur J Appl Physiol Occup Physiol. 1998; 78:296–302. https://doi.org/10.1007/s004210050423 PMID: 9754968

46. Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G, et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol. 2009; 20:604–12. https://doi.org/10.1016/j.ajpnp.2008.1681/ASN.2008060628 PMID: 19158350

47. Li W, Moylan JS, Chambers MA, Smith J, Reid MB. Interleukin-1 stimulates catabolism in C2C12 myotubes. Am J Physiol Cell Physiol. 2009; 297:C706–14. https://doi.org/10.1152/ajpcell.00626.2008 PMID: 19625606
48. Hao Y, Jackson JR, Wang Y, Edens N, Pereira SL, Alway SE. beta-Hydroxy-beta-methylbutyrate reduces myonuclear apoptosis during recovery from hind limb suspension-induced muscle fiber atrophy in aged rats. Am J Physiol Regul Integr Comp Physiol. 2011; 301:R701–15. https://doi.org/10.1152/ajpregu.00840.2010 PMID: 21697520

49. Baptista IL, Silva WJ, Artioli GG, Guilherme JP, Leal ML, Aoki MS, et al. Leucine and HMB differentially modulate proteasome system in skeletal muscle under different sarcopenic conditions. PLoS One. 2013; 8:e76752. https://doi.org/10.1371/journal.pone.0076752 PMID: 24124592

50. Schaap LA, Pluijm SM, Deeg DJ, Harris TB, Kritchevsky SB, Newman AB, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009; 64:1183–9. https://doi.org/10.1093/gerona/glp097 PMID: 19622801

51. Giresi PG, Stevenson EJ, Theilhaber J, Koncarevic A, Parker J, Fielding RA, et al. Identification of a molecular signature of sarcopenia. Physiol Genomics. 2005; 21:253–63. https://doi.org/10.1016/j.physigen.0243.2004 PMID: 15687482

52. Clavel S, Coldefy AS, Kurkdjian E, Salles J, Margaritis I, Derijard B. Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat Tibialis Anterior muscle. Mech Ageing Dev. 2006; 127:794–801. https://doi.org/10.1016/j.mad.2006.07.005 PMID: 16949134

53. Ciciliot S, Rossi AC, Dyar KA, Blaauw B, Schiaffino S. Muscle type and fiber type specificity in muscle wasting. Int J Biochem Cell Biol. 2013; 45:2191–9. https://doi.org/10.1016/j.biocel.2013.05.016 PMID: 23702032

54. Nilwik R, Snijders T, Leenders M, Groen BB, van Kranenburg J, Verdijk LB, et al. The decline in skeletal muscle mass with aging is mainly attributed to a reduction in type II muscle fiber size. Exp Gerontol. 2013; 48:492–8. https://doi.org/10.1016/j.exger.2013.02.012 PMID: 23425621